Alivus Life Sciences Ltd

NSE: ALIVUS · BSE: 543322 · Pharmaceuticals & Biotechnology · 23 announcements

Share price: ₹1,384.70
Market cap: ₹17,000 Cr
Revenue (annual): ₹2,552 Cr
Net profit (annual): ₹564.5 Cr
P/E (TTM): 28.2×Sector 47.4×
Promoter holding: 74.87%+0.00% QoQ
FII holding: 5.54%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 5 Financial Results 4 Results Update 2 Merger & Restructuring 2 Employee Stock Options 2 Board Meeting Date 2 Annual General Meeting 2 Other Announcement 1 Debt & Borrowing 1 Business Update 1 Annual Report 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

16 Sep 2026 13:17 IST BSE

Merger & Restructuring

Alivus Life Sciences Merger & Restructuring Worth ₹0.9 Cr

Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.

Value: ₹0.90 Cr

Read the filing ↗

18 Aug 2026 17:24 IST BSE

Merger & Restructuring

Alivus Life Sciences Merger & Restructuring Worth ₹9.12 Cr

Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.

Value: ₹9.12 Cr

Read the filing ↗